Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process
Xtant Medical Holdings, Inc. reported total revenue of $24.3 million for the third quarter of 2026, down from $33.3 million in the same period of 2025. The company recorded a net loss of $3.6 million, or $0.03 per share, compared to a net income of $1.3 million, or $0.01 per diluted share, in the third quarter of 2025. Adjusted EBITDA was a loss of $1.5 million, compared to a gain of $4.5 million in the prior-year period. Chairman of the Board Stavros Vizirgianakis expressed disappointment with the financial performance, noting it was the second consecutive quarter missing guidance. In response to these results, the Board has initiated a strategic review process to evaluate options for the company.